Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis

Hans-Peter Hartung, Ralph H.B. Benedict, Thomas Berger, Robert A. Bermel, Bruno Brochet, William M. Carroll, Mark S. Freedman, Trygve Holmøy, Rana Karabudak, Carlos Nos, Francesco Patti, Amy Perrin Ross, Ludo Vanopdenbosch, Timothy Vollmer, Jens Wuerfel, Susanne Clinch, Karen Kadner, Thomas Kuenzel, Inessa Kulyk, Catarina Raposo, Gian-Andrea Thanei, Joep Killestein

Open source

DOI: 10.1212/wnl.0000000000210049
Published: 2024-12-24
Container: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1212/wnl.0000000000210049,
  title = {Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis},
  author = {Hans-Peter Hartung and Ralph H.B. Benedict and Thomas Berger and Robert A. Bermel and Bruno Brochet and William M. Carroll and Mark S. Freedman and Trygve Holmøy and Rana Karabudak and Carlos Nos and Francesco Patti and Amy Perrin Ross and Ludo Vanopdenbosch and Timothy Vollmer and Jens Wuerfel and Susanne Clinch and Karen Kadner and Thomas Kuenzel and Inessa Kulyk and Catarina Raposo and Gian-Andrea Thanei and Joep Killestein},
  year = {2024},
  journal = {Neurology},
  doi = {10.1212/wnl.0000000000210049},
  url = {https://doi.org/10.1212/wnl.0000000000210049}
}

RIS

TY  - JOUR
TI  - Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis
AU  - Hans-Peter Hartung
AU  - Ralph H.B. Benedict
AU  - Thomas Berger
AU  - Robert A. Bermel
AU  - Bruno Brochet
AU  - William M. Carroll
AU  - Mark S. Freedman
AU  - Trygve Holmøy
AU  - Rana Karabudak
AU  - Carlos Nos
AU  - Francesco Patti
AU  - Amy Perrin Ross
AU  - Ludo Vanopdenbosch
AU  - Timothy Vollmer
AU  - Jens Wuerfel
AU  - Susanne Clinch
AU  - Karen Kadner
AU  - Thomas Kuenzel
AU  - Inessa Kulyk
AU  - Catarina Raposo
AU  - Gian-Andrea Thanei
AU  - Joep Killestein
PY  - 2024
JO  - Neurology
DO  - 10.1212/wnl.0000000000210049
UR  - https://doi.org/10.1212/wnl.0000000000210049
ER  -

APA

Hartung, H., Benedict, R. H., Berger, T., Bermel, R. A., Brochet, B., Carroll, W. M., Freedman, M. S., Holmøy, T., Karabudak, R., Nos, C., Patti, F., Ross, A. P., Vanopdenbosch, L., Vollmer, T., Wuerfel, J., Clinch, S., Kadner, K., Kuenzel, T., Kulyk, I., Raposo, C., Thanei, G., & Killestein, J. (2024). Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis. Neurology. https://doi.org/10.1212/wnl.0000000000210049

Source records

crossref · retrieved 2026-09-26T15:04:15.814Z